- Report
- December 2025
- 390 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 220 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 166 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 373 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 245 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 244 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 324 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 184 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 193 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 246 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 197 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 194 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 194 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 273 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- May 2025
- 110 Pages
Global
From €4195EUR$4,750USD£3,669GBP
- Report
- October 2025
- 250 Pages
Global
From €3965EUR$4,490USD£3,468GBP
- Report
- October 2025
- 250 Pages
Global
From €3965EUR$4,490USD£3,468GBP
- Report
- October 2025
- 250 Pages
Global
From €3965EUR$4,490USD£3,468GBP
- Report
- September 2025
- 250 Pages
Global
From €3965EUR$4,490USD£3,468GBP
- Report
- September 2025
- 250 Pages
Global
From €3965EUR$4,490USD£3,468GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more